跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
GLP-1 RA
首页
药物
GLP-1 RA
GLP-1 RA
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action
US 10610572 B2
申请人: ADOCIA
优先权: 2017
CN
EP
US
WO
8 件公开
A GIP/GLP1 FOR USE IN THERAPY
EP 4587117 A4
申请人: LILLY CO ELI
优先权: 2022
EP
US
WO
3 件公开
PHARMACEUTICAL FORMULATION OF GLUCAGON-LIKE PEPTIDE -1 RECEPTOR AGONIST PEPTIDE FOR SUBLINGUAL DELIVERY
US 20250241994 A1
申请人: IMMUNWORK INC
优先权: 2024
CN
US
WO
3 件公开
COMPOSITIONS COMPRISING AT LEAST AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST
EP 3858373 A1
申请人: ADOCIA
优先权: 2020
CN
EP
2 件公开
EP 4129324 A1
申请人: ADOCIA
优先权: 2021
EP
A FUSION PEPTIDE FOR ACTIVATION OF THE APJ AND / OR GLP-1 RECEPTORS
EP 4720107 A1
申请人: UNIV ULSTER
优先权: 2023
EP
WO
2 件公开
COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS
US 20260091010 A1
申请人: EFIL BIOSCIENCE INC
优先权: 2024
US
WO
2 件公开
Insulin producing cells derived from pluripotent stem cells
US 9404087 B2
申请人: REVEL MICHEL
优先权: 2011
US
2 件公开
Combination of organic compounds
CN 101043916 A
申请人: NOVARTIS AG
优先权: 2004
CN
COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHIPHILIC COMPOUND CONTAINING HYDROPHOBIC RADICALS
CN 112805025 A
申请人: ADOCIA
优先权: 2018
CN
PHARMACEUTICAL COMPOSITION IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST A RAPID ACTING INSULIN ANALOG AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION
EP 3915571 A1
申请人: ADOCIA
优先权: 2020
EP
EP 3915572 A1
申请人: ADOCIA
优先权: 2020
EP
第 1 / 3 页
上一页
下一页
药物
反馈